Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? - Test2 - elhamkhani - TriplyDB

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

http://www.wikidata.org/entity/Q26777994

about

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?Association of Increasing GFR with Change in Albuminuria in the General Population.Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.

P2860

Q33845734-38134691-1447-421B-B5B1-45FBED69180D Q38667712-124E0565-686D-4D45-A1E3-BE27C2A27903 Q40561359-1E228F14-10AC-469D-9FA7-D86B461FC85D Q42876331-C23B7236-00C4-4AF5-8DD5-123324672379 Q48141985-C73699E4-D4CD-4AC3-95BE-782990944AF2

P2860

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

http://www.wikidata.org/entity/Q26777994

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

@ast

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

@en

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

@nl

type

label

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

@ast

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

@en

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

@nl

prefLabel

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

@ast

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

@en

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

@nl

P1433

Q26777994-4789F8F8-9626-4B5C-90F1-4B832C900E3E

P1476

Q26777994-78C3920F-804D-493D-8C85-270B52B0799A

P2093

Q26777994-792DAF79-BDC1-442C-A2FB-BE4A6F0B1825

Q26777994-A55571FE-CF29-4EE7-9CC4-77E7BE8E893E

Q26777994-B86758E7-A8BB-4BE6-B278-C0F9F11D3052

Q26777994-EC455183-F60C-41A4-9907-D8ED74BB8FD4

Q26777994-FFEE49FA-5CB1-4AA3-BA77-F40417B28C0B

P2860

Q26777994-00D98226-6573-4838-AD97-6BC5EB1E5B86

Q26777994-063AF606-7505-4551-8AB8-F57C4CC03E80

Q26777994-0CBDFF2F-60CA-4CB5-A0A2-746180034E7C

Q26777994-0E1909F9-4537-4F74-8B95-762BF45CC58D

Q26777994-10293B9F-3FD3-4D43-ADDF-4188EE5478AE

Q26777994-13909718-6DCC-4C24-9704-4EA3133A888C

Q26777994-15CE1732-FF09-42EA-A5F0-21B0E78ECC84

Q26777994-16CC6452-3B91-4A0E-9A21-796CA1CBC905

Q26777994-17FFEDEF-FB39-4F6F-8A89-D52BFE1405F2

Q26777994-1DE2A31A-DBC9-4E9F-9006-6537BB6BD822

P304

Q26777994-342A1661-67F3-48C4-842B-1028DCF4D056

P31

Q26777994-F4A12C8F-1440-469D-8C84-E52F09156688

P356

Q26777994-8F9A4685-68E6-4CF9-B413-5263B3CB0544

P407

Q26777994-25794934-0AE6-4D4C-8F75-A29E0ECBD92E

P433

Q26777994-D661DFFC-46AE-4963-8033-86517B589F35

P478

Q26777994-9DB2E502-DC2B-467D-813D-723D476F2474

P50

Q26777994-4A6FEBA2-BE89-4C9A-A51C-CA2EB07FBF75

P577

Q26777994-2155988F-36DE-41E4-BF49-660E08900957

P5875

Q26777994-A102AE1C-7B2E-4FDA-8A71-0A4BE9F2FB01

P698

Q26777994-CE5CB394-9340-489A-B7E8-D7C350098290

P932

Q26777994-F8465335-D7E4-46EF-AC27-F431B7343170

P356

P1433

Journal of Clinical Medicine

P1476

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

@en

P2093

Alberto Martínez-Castelao

http://www.w3.org/2001/XMLSchema#string

Javier Nieto

http://www.w3.org/2001/XMLSchema#string

Jose Luis Górriz

http://www.w3.org/2001/XMLSchema#string

Luis M Pallardó

http://www.w3.org/2001/XMLSchema#string

Pablo Molina

http://www.w3.org/2001/XMLSchema#string

P2860

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Renal effects of dapagliflozin in patients with type 2 diabetes

The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years

Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.

Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

P304

1866-1889

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/JCM4101866

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Juan F Navarro-González

P577

2015-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283325264

http://www.w3.org/2001/XMLSchema#string

P698

26512703

http://www.w3.org/2001/XMLSchema#string

P932

4626660

http://www.w3.org/2001/XMLSchema#string